-- エーザイ（東証：4523）は、アルツハイマー病治療薬「レケンビ」の全世界売上高が、3月期（3月期）の暫定値で880億円に達したと、木曜日に東京証券取引所に提出した書類で明らかにした。 売上高の内訳は、米国が446億円、日本が244億円、中国が124億円となっている。
Related Articles
Asia
Piccadilly Agro Industries' Consolidated Net Profit Rises in Fiscal Q4
Piccadilly Agro Industries' (NSE:PICCADIL,BOM:530305) consolidated net profit rose to 452.3 million Indian rupees in the fiscal fourth quarter ended March 31, from 398.0 million rupees a year ago.Earnings per share came in at 4.62 rupees from 4.22 rupees a year earlier, the alcoholic beverages manufacturer said in a filing to the Indian stock exchanges on Tuesday.Revenue from operations in fiscal Q4 also increased to 3.60 billion rupees from 2.72 billion rupees a year ago.
$BOM:530305$NSE:PICCADIL
Asia
Shenzhen Hepalink Pharmaceutical's Profit Rises 20% in Q1
Shenzhen Hepalink Pharmaceutical (HKG:9989, SHE:002399) posted net profit attributable to shareholders of 187.6 million yuan for the first quarter, up 20% from 156.6 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.Hong Kong-listed shares of the pharmaceutical firm were up over 1% in Thursday's late morning trade.Earnings per share came in at 0.1278 yuan, compared with 0.1067 yuan a year earlier.Operating revenue fell 4.6% to 1.33 billion yuan from 1.39 billion yuan in the prior-year period.
$HKG:9989$SHE:002399
Asia
Stoneweg Europe Stapled Trust Completes Sale of Polish Office Asset for EUR23 Million
Stoneweg Europe Stapled Trust (SGX:SET) completed the divestment of a Polish office asset named Riverside Park for 22.5 million euros, according to a Thursday filing with the Singapore Exchange.The divestment is part of the trust's strategy to recycle capital, with proceeds to be used to invest in logistics and data centers.
$SGX:SET